tbuckley/cabot-search huggingface dataset:
Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges
Authors: Ming Ming Wen, Noha S. El-Salamouni, Wessam M. El-Refaie, Heba A. Hazzah, Mai M. Ali, Giovanni Tosi, Ragwa M. Farid, Maria J. Blanco-Prieto, Nashiru Billa, Amira S. Hanafy
Journal: Journal of Controlled Release (2016)
Features of Herpesviruses (CMV, EBV, HHV6) Infections and Immune Reconstitution after Allogeneic Stem Cell Transplantation (allo-SCT) Using Alternative Donors: Comparison Between Matched Unrelated Donors (MUD) and Cord Blood (CB) as Stem Cell Source.
Authors: Patrice Chevallier, Thierry Guillaume, Lucie Planche, Imen Hebia-Fellah, Celine Bressollette- Bodin, Fanny Rialland, Marianne Coste-Burel, Sameh Ayari, Jacques Delaunay, Valerie Horvais, Jean-Luc Harousseau, Mohamad Mohty, Berthe-Marie Imbert-Marcille
Journal: Blood (2008)
Impact of Non-JAK2 Molecular Mutations and Cryptic SNP Lesions in Myelofibrosis Patients Treated with Ruxolitinib
Authors: Jing Ai, Valeria Visconte, Ali Tabarroki, Ahmad Zarzour, Christopher Gerace, Karam Al-Issa, Evan Hsi, Yasmine Hirbawi, Betty K. Hamilton, Eric D. Hsi, Heesun J. Rogers, Ramon V. Tiu
Journal: Blood (2014)
Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era
Authors: Gita Thanarajasingam, Matthew J Maurer, Umar Farooq, Patrick B. Johnston, Carrie Thompson, Stephen Ansell, Luis Porrata, William Macon, Sergei Syrbu, James Cerhan, Thomas M. Habermann, Thomas E. Witzig, Brian K Link, Grzegorz S. Nowakowski
Journal: Blood (2015)
The Second Signal in Antigen-Presenting Cells: Complementary JAK1/JAK2 and CD40 Signalling Mediate Pro-Inflammatory Activation.
Authors: Michael Conzelmann, Elena Rodionova, Michael Hess, Annika Zota, Thomas Giese, Andreas Wagner, Stephen Breit, Markus Hecker, Anthony D. Ho, Peter Dreger, Thomas Luft
Journal: Blood (2008)
Placental Growth Factor (PlGF) Synergizes with Granulocyte Colony-Stimulating Factor (G-CSF) for the Mobilization of Primitive and Committed Peripheral Blood Progenitor Cells (PBPCs) in Nonhuman Primates.
Authors: Carmelo Carlo-Stella, Massimo Di Nicola, Paolo Longoni, Raffaella Milani, Marco Milanesi, Michele Magni, Loredana Cleris, Franca Formelli, Virgilio Pace, Francesco Colotta, Alessandro M. Gianni
Journal: Blood (2004)
SAT0237 Nailfold Capillaroscopy Findings in Scleroderma Patients – Prognostic Implications
Authors: L.C. Teixeira, I. Cordeiro, S. Sousa, A.C. Duarte, J. Canas da Silva, A. Cordeiro, M.J. Santos
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Nailfold <i>capillaroscopy</i> (NCP) is a useful tool for the diagnosis and follow-up of systemic rheumatic diseases and represents one of the best methods to evaluate microvascular abnormalities. <h3>Objectives</h3> To characterize NCP findings of patients with Systemic Sclerosis (SSc), and understand how NCP associates with the presence of digital ulcers, gastrointestinal involvement, pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). <h3>Methods</h3> NCP findings of adult patients with SSc followed-up in our center were reviewed. Demographic and clinical features were collected. Nonparametric tests were used to determine potential associations between capillaroscopy findings/patterns and the presence of digital ulcers, gastrointestinal involvement, PAH and ILD. <h3>Results</h3> In total, 52 out of 103 patients with SSc had at least one NCP result available. Forty five were female (86.5%) and seven male (13.5%), the age was 56.6 ±13.2 years and disease duration 10.9 ±10.5 years. Thirty one (59.6%) had limited cutaneous SSc, seven (13.5%) diffuse cutaneous SSc, ten (19,2%) VEDOSS, three (5.8%) overlap syndromes and one (1.9%) SSc sine scleroderma. (table 1). The most frequent NCP findings were hemorrhages (54.7%) megacapillaries (54.7%), and capillary dilatations (52.8%). We found that digital ulcers were significantly associated with the existence of avascular areas (p=0.02), and with neoangiogenesis (p=0.03) in univariate analysis, but were not associated with any capillaroscopy pattern. Looking to interstitial lung disease, there is a trend for association with the presence of avascular areas (p=0.056). Only one patient had PAH confirmed by right heart catheterization. In this case NCP showed giant capillaries, neoangiogenesis and avascular areas. There was also a trend for association between avascular areas and higher values of NT pro BNP (p=0.078). Gastrointestinal involvement was not significantly associated with NCP findings (table 2). <h3>Conclusions</h3> In our study the presence of avascular areas and neoangiogenesis in NCP was significantly associated with the existence of digital ulcers. Also, ILD and higher values of NT-proBNP were more common in patients who present avascular areas. These results suggest that abnormalities detected in the NCP might help predict organ involvement, although long term follow up and greater numbers of patients are needed in order to confirm the prognostic value of NCP findings. <h3>References</h3> Mannarino E, Pasqualini L, Fedeli F, Scricciolo V, Innocente S. Nailfold capillaroscopy in the screening and diagnosis of Raynaud9s phenomenon. Angiology 1994; 45: 37–42 <h3>Disclosure of Interest</h3> None declared
Short Course Infliximab and Extracorporeal Photopheresis As Therapy For Steroid-Refractory Acute Gvhd In Matched Related and Unrelated Allogeneic Hematopoietic Cell Transplant (HCT)
Authors: Jared Klein, James L Slack, Lisa Sproat, Veena Fauble, Nandita Khera, Jose F. Leis, Pierre Noel, Sergio Torloni, Roberta H. Adams, Jeff Betcher
Journal: Blood (2013)
THU0631 Incidence of Serious Adverse Events in Patients with Rheumatoid Arthritis Exposed To Biologic Therapies. Results from Biobadabrasil Registry
Authors: R. Ranza, I. Laurindo, D. Titton, M. Bertolo, W. Bianchi, C. Brenol, M. Bustamante, H. Carvalho, G. Castro, I. Costa, A. Duarte, V. Fernandes, M. Freire, P. Louzada, J. Maciera, J. Miranda, J. Moraes, I. Pereira, G. Pinheiro, M. Sauma, B. Stadler, R. Toledo, V. Valim, C. Baaklini, M. Descalzo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The safety profile of biologic drugs might have substantial regional differences. Since 2009, the Brazilian Society of Rheumatology runs BiobadaBrasil, a registry for monitoring of biologic therapies in rheumatic diseases, in collaboration with other Latin America countries (BiobadaAmerica) and with Biobadaser <h3>Objectives</h3> To report the incidence of serious adverse events (SAE) in Rheumatoid Arthritis (RA) patients exposed to biologic drugs in Brazil <h3>Methods</h3> BiobadaBrasil counts on thirty two centers, from almost all Brazilian states, that prospectively include patients with active rheumatic diseases who started a biologic drug or a synthetic DMARD as a parallel control group. A constant three level monitory of data quality is maintained (online, by phone and "in situ"). This study focuses on SAE (for definition: Protocolo 1.1 at https://biobadaser.ser.es/biobadamerica/Brasil/cgi-bin/upload/documentacion.aspx) in RA patients exposed to biologics from January 2009 to June 2015. Time of exposure was set from start of the drug to the date of last administration or censorship. Continuous variables were expressed as mean with standard deviation (SD). SAE incidence rate was calculated per 1000 patient/years with 95%CI <h3>Results</h3> Out of a total of 1649 subjects with RA, 1121 were exposed to biologics (4735 p/y), 91% a-TNFs, follow-up 2.8 (2.2) yrs, 85% females, at baseline: age 50 (14) yrs, disease duration 9 (8) yrs, DAS28 5.4 (1.4). Controls were 528 (1971 p/y), follow-up 3.6 (2.2) yrs, 86% females, at baseline: age 54 (13) yrs, disease duration 6 (8) yrs, DAS28 5.1 (3.1). The incidence rates of SAE in the biologics and control groups were 86 [78, 94] vs 34 [27, 44] (ratio 2.5 [1.9, 3.3], p&lt;0.001). There was no statistical difference in SAE incidence between a-TNFs and non-a-TNF biologics. Among a-TNFs, Adalimumab was associated with less SAE (64 [53,79]) compared with Etanercept (93 [77,113] p&lt;0.01) and Infliximab (102 [86,122] p=0.0003). SAE were more frequent with subsequent a-TNF than with the first, 107 [87, 132] vs 79 [70, 90] (ratio 1.4 [1.1, 1.7] p=0.0078). Among SAEs with biologics, serious infections account for half of the events (43 [37–49]) <h3>Conclusions</h3> In the BiobadaBrasil registry the incidence of SAE is 2 fold higher with biologics than with synthetic DMARDs, and higher with subsequent a-TNF than with the first <h3>Acknowledgement</h3> for data monitoring P Cabral, for contributing to BiobadaBrasil registry, L.Barbosa, W.Chahade, A.Hayata, A.Kakehasi, M.Pinheiro, A.Ranzolin, M.Scheinberg, F.Sztajnbok, I.Silveira <h3>Disclosure of Interest</h3> None declared
Treatment of Diffuse Large B Cell Lymphoma with CHOP and Rituximab. Results of a Multicenter Study with 236 Patients.
Authors: Javier De la Serna, R. Ayala, M. Canales, P. Giraldo, M. de la Cruz-Mora, A. Rueda, C. Montalban, J. Queizan, J. Garcia-Vela, F. Feliu, C. Calle, B. Hernandez, R. Hernandez, F. Solano, J. Peñalver, J. Ojanguren, J. Sanchez-Guilarte, C. Morante, C. Nicolas, A. Roman, L. Palomera, J. Diaz-Mediavilla
Journal: Blood (2005)
Douglas Stewart Robbie
Authors: Neil Robbie
Journal: BMJ (2016)

Douglas Stewart Robbie was born to Margaret and George Robbie, brother of Glen and Yvonne. He was raised in Aberdeen and was joint dux at Aberdeen Grammar School in 1948. Although he was offered a scholarship to Fettes College in Edinburgh, his parents preferred the local school, from where he progressed to Aberdeen University to study medicine and qualified with commendation. He married Terry, whom he had met in Aberdeen, in 1956. From his houseman post at Aberdeen Royal Infirmary, where he worked in wards 2 and 9, he went south to Hampshire to join the Royal Army Medical Corps, from 1955 to 1957. At Crookham he was a captain under the notorious Colonel Benson (“there is BULL and there is BULL!”). While stationed there he was asked to parachute into Suez, and nearly did so, but was somewhat grateful to be relieved of this duty when somebody else keenly requested to take his place. While at Crookham he read a lot on the theory of anaesthesia, in preparation for his job as senior house officer at the Westminster and Brompton hospitals in London, where he subsequently was registrar and senior registrar. After conducting some important research on profound hypothermia, and on completion of his FFARCS, …
Heterogeneous Interactions of Leukemic and Control Bone Marrow Stroma Cells with an AML Cell Line and AML Leukemic Blasts.
Authors: Ulrike Buttkereit, Sana Mohamad, Monika Lindemann, Joachim R. Goethert, Bertram Opalka, Jan Duerig, Ulrich Duehrsen
Journal: Blood (2010)
Quantitative Analysis of Chimerism Using Insertion/Deletion Polymorphisms Is An Useful Predictor of Relapse After Allogeneic Stem Cell Transplantation for Acute Leukemia.
Authors: Nathalie Jacque, Nathalie Dhédin, Jean Louis Golmard, Madalina Uzunov, Stéphanie Nguyen, Julien Lazarovici, Laurent Sutton, Jean-Paul Vernant, Dominique Bories
Journal: Blood (2009)
FRI0412 Mannose Binding Lectin Gene Polymorphisms in Spondyloarthropathies
Authors: A. Yildirim, O. Kudas, I. Turk, F. Yildiz, S. Dinkci, E. Erken
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Genetic and environmental factors are known to play a role in the pathogenesis of spondyloarthropathies (SPA). Mannose binding lectin (MBL) which is a member of collectin family proteins, is an important component of innate immunity. Low levels of MBL is associated with susceptibility to infections. Several variants of MBL gene may result in MBL deficiency. MBL gene polymorphisms and MBL deficiency are shown to be related with several autoimmune and inflammatory diseases. <h3>Objectives</h3> The relationship between the MBL levels or MBL gene polymorphisms and SPA predisposition has previously been investigated in a few small studies with conflicting results. In this particular study, we aimed to assess the relationship of the MBL genes in the develepoment of SPA in a group of Turkish patients. <h3>Methods</h3> Study included 132 patients with SPA (75 female, 57 male, mean age: 43.0±12.4) and 87 healthy subjects (58 women, 29 men, mean age: 40.3±13.4) as control group. Eighty nine of the SPA patients had ankylosing spondylitis (AS) and 43 had non-AS SPA. MBL gene single nucleotide polymorphisms (SNP) in the codons 52, 54 and 57 of exon 1 were studied by sequencing method. <h3>Results</h3> G54D G&gt;A polymorphism was not different between the patient and the healthy control groups (p=0.291). The frequencies of R52C C&gt;T and G57E G&gt;A polymorphisms were found to be significantly higher in the SPA patients than those of the healthy controls (p=0.019 and 0.001 respectively). While the non-AS subgroup showed significancy for both R52C C&gt;T and G57E G&gt;A polymorphisms (p=0.004 and 0.000 respectively), the AS subgroup showed significancy only for G57E G&gt;A (p=0.113 and 0.014 respectively). Clinical characteristics of either AS or non-AS SPA patients were not associated with any of the MBL polymorphisms. In a previous study, haplotypes of MBL genetic polymorphisms were found to be associated with AS in Korean patients. Our study is the first one from Turkey indicating the relationship between SPA9s and MBL gene polymorphisms. <h3>Conclusions</h3> Even though we had rather small sample size, our results showed significantly higher R52C C&gt;T and G57E G&gt;A polymorphisms in Turkish patients with SPA. Therefore we may suggest that MBL gene polymorphisms could be related with the predisposition of the disease. <h3>References</h3> Churl Hyun Im et al.: Mannose-binding lectin 2 gene haplotype analysis in Korean patients with ankylosing spondylitis. Rheumatol Int (2012) 32:2251–5 Aydin SZ et al: Mannose binding lectin levels in spondyloarthropathies. J Rheumatol. (2007) Oct;34(10):2075–7 Aydin SZ et al: Mannose binding lectin levels are not related to radiographic damage in ankylosing spondylitis Rheumatol Int (2010) 30:415–7 <h3>Disclosure of Interest</h3> None declared
Gradual Versus Abrupt Smoking Cessation
Authors: Macé M. Schuurmans
Journal: Annals of Internal Medicine (2016)

Letters15 November 2016Gradual Versus Abrupt Smoking CessationMacé M. Schuurmans, MDMacé M. Schuurmans, MDFrom University Hospital Zurich, Zurich, Switzerland.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0403 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Lindson-Hawley and colleagues (1) report a randomized trial comparing 2 smoking cessation strategies using NRT (1). The abrupt-cessation strategy led to higher quit rates than the gradual-cessation strategy at 1 and 6 months.However, when looking at the details, one realizes that “abrupt cessation” is not what one generally would expect: Complete cessation on the target quit date and immediate initiation of NRT, as generally recommended in the package inserts of such therapy. This was not done. The abrupt strategy in this trial was less “abrupt” and more prepared than it may seem because it included precessation ...References1. Lindson-Hawley N, Banting M, West R, Michie S, Shinkins B, Aveyard P. Gradual versus abrupt smoking cessation: a randomized, controlled noninferiority trial. Ann Intern Med. 2016;164:585-92. [PMID: 26975007]. doi:10.7326/M14-2805 LinkGoogle Scholar2. Schuurmans MM, Diacon AH, van Biljon X, Bolliger CT. Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial. Addiction. 2004;99:634-40. [PMID: 15078238] CrossrefMedlineGoogle Scholar3. Moon MA. Cold turkey better for smoking cessation. CHEST Physician. 14 March 2016. Accessed at www.mdedge.com/chestphysician/article/107353/pulmonology/cold-turkey-better-smoking-cessation on 6 October 2016. Google Scholar Author, Article, and Disclosure InformationAffiliations: From University Hospital Zurich, Zurich, Switzerland.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L16-0403. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoGradual Versus Abrupt Smoking Cessation Nicola Lindson-Hawley , Miriam Banting , Robert West , Susan Michie , Bethany Shinkins , and Paul Aveyard Gradual Versus Abrupt Smoking Cessation John R. Hughes and Elias M. Klemperer Gradual Versus Abrupt Smoking Cessation Robert West , Nicola Lindson-Hawley , and Paul Aveyard Metrics Cited bySmoking reduction interventions for smoking cessation 15 November 2016Volume 165, Issue 10Page: 741-742KeywordsDisclosureNicotineRandomized trialsSmoking cessation ePublished: 15 November 2016 Issue Published: 15 November 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
FRI0560 The Increase in The Nationwide Incidence of Inflammatory Rheumatic Diseases in Finland during This Millennium:
Authors: V. Rantalaiho, H. Kautiainen, L. Virta, K. Puolakka
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> With the growing knowledge, the diagnostic and therapeutic opportunities of most inflammatory rheumatic diseases have intensified during the recent decades. This has led to improved functional outcomes in the vast majority of patients, but also to a certain dependency of specialist care in these patients, which, in the face of the current decreasing numbers of practicing rheumatologists raises concerns about the abundance of the health care resources. Some earlier reports have shown a decreasing incidence of rheumatoid arthritis (RA) in Eastern Finland; however there is no data on other diagnoses, and the experience from clinical practice contradicts these findings. Thus, to be able to optimally meet the future needs of rheumatological therapy, the total burden of new inflammatory rheumatic diseases needs to be assessed. <h3>Methods</h3> From the Finnish nationwide register maintained by the Social Institute of Insurance (SII) we collected data on all patients granted a new special reimbursement on medications for various inflammatory rheumatic diseases from January 1st 2000 to December 31st 2014. The diagnoses were: juvenile arthritis (all patients aged 0–16 years with ICD-10 diagnosis M02-M46), and for patients &gt;16 years, seropositive rheumatoid arthritis (RA) (M05), seronegative RA (M06), spondylarthritis (M45-M46), unspecified arthritis (M13) and psoriatic arthritis (L40.5). The total number of new patients and the incidences for each diagnosis /100 000 patient years in these age groups were counted in 3-year cohorts. <h3>Results</h3> During the observation time altogether 54 658 patients (61.7% female) with a new diagnosis of a rheumatic disease and an initiated treatment were identified. The total incidence of inflammatory rheumatic diseases increased linearly from the first cohort9s 63/100 000/patient years to the last cohort9s (2012–14) 76/100 000/patient years, and the absolute yearly number of newly diagnosed patients increased 1.39-fold during the follow-up. The characteristics of each diagnosis group are presented in the Table. <h3>Conclusions</h3> The total burden new of rheumatic diseases has increased during this millennium. The incidence of seropositive RA has remained stable and only that of seronegative RA has decreased slightly. However, the incidence unspecified and psoriatic arthritis, as well as spondylarthritis has increased clearly. Thus, with increasing numbers of new patients the recourses for rheumatological treatment should increase accordingly to face their needs. <h3>Disclosure of Interest</h3> None declared
Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry
Authors: Lisa Pleyer, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Werner Linkesch, Michael Pfeilstöcker, Eva Maria Autzinger, Christoph Tinchon, Thamer Sliwa, Alois Lang, Wolfgang R. Sperr, Dietmar Geissler, Peter Krippl, Daniela Voskova, Dieter H. Rossmann, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl-Spandl, Georg Theiler, Peter Valent, Otto Eckmüllner, Richard Greil
Journal: Blood (2014)
Has Cytogenetic Evolution Any Prognostic Relevance in Myelodysplastic Syndromes (MDS)? A Study on 153 Patients.
Authors: Paolo Bernasconi Prof, Catherine Klersy, Marina Boni, Paola Maria Cavigliano, Silvia Calatroni, Ilaria Giardini, Barbara Rocca, Rita Zappatore, Irene Dambruoso, Marilena Caresana, Mario Lazzarino Prof
Journal: Blood (2007)
The Cost-Effectiveness of Rituximab, Cyclophosphamide, Vincristine and Prednisolone (RCVP) Compared with CVP for the Treatment of Follicular Non-Hodgkin’s Lymphoma (NHL) in the UK.
Authors: Gavin Lewis, Robert E. Marcus, Stephen J. Proctor, Marlene Gyldmark, James Creeden, Rick Aultman, Fred Jost
Journal: Blood (2006)
The war on drugs has failed: doctors should lead calls for drug policy reform
Authors: Fiona Godlee, Richard Hurley
Journal: BMJ (2016)

Evidence and ethics should inform policies that promote health and respect dignity

People have always consumed psychoactive substances, risking harm.1 2 A quarter of a billion adults—one in 20 worldwide—took an illegal drug such as cannabis, cocaine, or heroin in 2014.3 A quarter of UK 15 year olds are estimated to have ever taken an illegal preparation of unknown quality and potency,4 and most street sex work and much acquisitive crime funds drug taking.5 6

Three United Nations treaties, the oldest from 1961, seek to “advance the health and welfare of mankind” by prohibiting the non-medical use of some drugs. To this end, countries criminalise producers, traffickers, dealers, and users at an annual cost of at least $100bn.7

But the effectiveness of prohibition laws, colloquially known as the “war on drugs,” must be judged on outcomes. And too often the war on drugs plays out as a war on the millions of people who use drugs, and disproportionately on people who are poor or from ethnic minorities and on women.1

Prohibition and stigma encourage less safe drug …
The Pan-Deacetylase Inhibitor Panobinostat Downregulates HIF-1α and VEGF and, Synergizes with Everolimus In Hodgkin Lymphoma Cell Lines
Authors: Manuela Lemoine, Daniela Buglio, Adam Jona, Enrico Derenzini, L. Jeffrey Medeiros, Donald A Berry, Anas Younes
Journal: Blood (2010)
Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE)
Authors: Lakshmanan Krishnamurti, Keith M. Sullivan, Naynesh R. Kamani, Edmund K Waller, Allistair Abraham, Federico Campigotto, Wandi Zhang, Shannon Smith, Kathryn L. Hassell, Laura Decastro, Catherine J Wu, Donna S. Neuberg, Mark C. Walters
Journal: Blood (2015)